Travere Therapeutics (NASDAQ:TVTX) Posts Quarterly Earnings Results, Misses Estimates By $0.78 EPS

Travere Therapeutics (NASDAQ:TVTX) issued its quarterly earnings data on Monday. The company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78), Briefing.com reports. The business had revenue of $41.40 million during the quarter, compared to the consensus estimate of $43.46 million. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. The firm’s quarterly revenue was up 34.0% compared to the same quarter last year. During the same quarter last year, the business earned ($1.27) EPS.

Travere Therapeutics Stock Down 0.6 %

Shares of NASDAQ TVTX traded down $0.04 during midday trading on Thursday, hitting $6.78. 49,157 shares of the stock traded hands, compared to its average volume of 1,268,325. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.41 and a current ratio of 3.47. Travere Therapeutics has a one year low of $5.12 and a one year high of $19.54. The business has a 50 day moving average price of $6.99 and a two-hundred day moving average price of $7.60. The company has a market cap of $516.03 million, a PE ratio of -4.24 and a beta of 0.69.

Wall Street Analyst Weigh In

TVTX has been the topic of several analyst reports. Guggenheim reissued a “neutral” rating on shares of Travere Therapeutics in a research note on Wednesday, March 27th. Wells Fargo & Company raised their price target on shares of Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a report on Friday, February 16th. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Travere Therapeutics in a research note on Tuesday. Wedbush restated an “outperform” rating and issued a $13.00 target price on shares of Travere Therapeutics in a report on Wednesday, April 17th. Finally, Canaccord Genuity Group increased their price target on Travere Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $16.69.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.